Jonathan D. Reiss

Stanford Neonatology Instructor, Clinical Metabolomics, Lipidomics, and ML Enthusiast, GirlDad, Retired Mediocre Tennis Player, Opinions my Own

[Jonathan D. Reiss @jonathandreiss]

@BrianKingNeo @Dr_KSGautham @EBNEO Is there something specific you’re skeptical about? There were aspects of this that made me question results. But every time we did further analyses, results stood up.

[Eric Topol @EricTopol]

Using multimodal A.I. to more accurately predict a person's risk of cancer (and other conditions) by combining proteomics and electronic health records https://t.co/wZtarbQbt5 @NimaAghaeepour @NatMachIntell open-access

[Nima Aghaeepour @NimaAghaeepour]

Collecting #omics data is expensive, but #EHR data is available for large patient cohorts for free!

In our latest @NatMachIntell paper, we show how deep learning + EHR data can supercharge omics models. Hard work by (soon to be Dr.) Samson Mataraso:
https://t.co/Ht3FFHgfXn

[Jonathan D. Reiss @jonathandreiss]

Early-career setback and future career impact | Nature Communications……this is interesting….. https://t.co/1pHOeWZvi2

[Jonathan D. Reiss @jonathandreiss]

@LindseyKnake @mcelroylab @nicupodcast @mistygoodlab @davidj_mcculley Agree. @mcelroylab fantastic episode. Loved hearing him and @mistygoodlab @davidj_mcculley muse on various topics.

[Jonathan D. Reiss @jonathandreiss]

IBT NEC trial results released. Take home seems to be ?NEC definitions resulted in negative primary outcomes. https://t.co/N6RimG3M6h

[C. Vivek Lal @CVivekLaL]

Thrilled to share our team’s @NatureComms paper on the 1st inhaled live biotherapeutics for chronic lung disease! Years of hard work & bold thinking led us to engineer “air as medicine.” Proud to see this work moving forward at @AlveolusBio with phase 1b trials soon! @UABHeersink @UABNews @anupamuab @uabpeds @atscommunity @ATS_RCMB @UABInnovation

https://t.co/WsFj6d2Jxa

[Jonathan D. Reiss @jonathandreiss]

@crmartin90 @neo_twiter Planning to attend!

[Jonathan D. Reiss @jonathandreiss]

@crmartin90 @Dr_CynBlanco Planning to attend!

[Michael Fischbach @mfgrp]

How to pick a problem. Today in @CellCellPress. 1/53
https://t.co/Id4YaXWuup

[Jonathan D. Reiss @jonathandreiss]

@ambaln @souvik_neo @drbretty Need to conduct trials that answer more than one question at a time. There are reasonable ways to do this.

[Jonathan D. Reiss @jonathandreiss]

@afif_elKhuffash If you need to be close to perfect, doesn’t that suggest your effect size for the intended exposure or pharmacotherapy of interest is incredibly small?

[Ravi Mangal Patel @ravimpatelmd]

Another trial showing no benefit of early treatment of a PDA

Selection, definition, etc. … yes, know the arguments that will come … but at some point shouldn’t trial evidence >> physiologic rationale (without evidence of benefit on outcomes)

https://t.co/Axc6ocvKMi

#neoEBM

[NeonatalResearch @NeonatalResearc]

Time to open the DOOR https://t.co/E7auAD832w
#NeonatalResearch
#NeoEBM
#NeoMastodon
Join me in the https://t.co/xHWO5pq61h

[N. Ambalavanan @ambaln]

Interesting!....Single-cell analysis of prenatal and postnatal human cortical development | Science https://t.co/ptXAXW0o1B

[Jonathan Swanson @urmed02]

Pretty good math. I had come up with 400 deaths annually. That now makes 2 deaths due to probiotics over a decade? It’s also not just mortality. Surgical NEC has significant impact on NDI. Evidence would suggest as bad as grade IV IVH

[Michael Snyder, PhD @SnyderShot]

Our new lipidomics paper is out--very cool, but understudied molecules. https://t.co/GV59XUfPvS